Skip to content
Medical Health Aged Care

Dementia Action Week starts Monday 18 September ‘Act Now for a Dementia-Friendly Future’

Dementia Australia 2 mins read

WHAT: Dementia Action Week 2023 is from Monday 18 September to Sunday 24 September, which includes World Alzheimer’s Day on Thursday 21 September. 

THEME: This year’s theme is ‘Act Now for a Dementia-Friendly Future’. Communities that take action to become more dementia-friendly have less fear and a greater understanding of dementia, as well as less stigma and discrimination of people living with dementia. 

CALL TO ACTION: Find out more information and download toolkits to help businesses, organisations and local governments become more dementia-friendly https://www.dementia.org.au/dementia-action-week  

SPOKESPEOPLE: Interviews are available with Dementia Australia representatives, Dementia Advocates, who are people with a living experience of dementia and Dementia Australia Honorary Medical Advisors. Images and video footage are also available on request.

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 400,000 Australians living with dementia, and the more than 1.5 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you. 

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au  

-Ends- 

Media contacts: David Gear, Media and Communications Advisor, 0427 204 297, [email protected] 

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines. 

Note to Editors: 

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:  

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.  


Contact details:

David Gear - 0427 204 297, [email protected]

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 17:10
Galderma Group AG

Galderma Welcomes Increased Equity Investment From L’Oréal

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.